Brevan Howard Capital Management LP Avidity Biosciences, Inc. Transaction History
Brevan Howard Capital Management LP
- $14.2 Billion
- Q3 2024
A detailed history of Brevan Howard Capital Management LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 5,728 shares of RNA stock, worth $196,527. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,728Holding current value
$196,527% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding RNA
# of Institutions
250Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$365 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$324 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$296 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$279 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$241 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.79B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...